Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conferences:
- Randall Lipps, Omnicell Chairman, President, Chief Executive Officer, and Founder; and Scott Seidelmann, Omnicell Executive Vice President, Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021 at 9:00 am ET.
- Peter Kuipers, Omnicell Executive Vice President, Chief Financial Officer, will present live at the 2021 Stephens Annual Investment Conference on Friday, December 3, 2021 at 10:00 am CT in Nashville, TN.
Live and archived webcasts of the presentations will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/
About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings.
Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 60,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.
To learn more, visit www.omnicell.com. From time to time, Omnicell may use the Company's investor relations site and other online social media channels, including its Twitter handle www.twitter.com/omnicell, LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure ("FD").
Omnicell and the Omnicell logo are registered trademarks of Omnicell, Inc. in the United States and other countries.
OMCL-E
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006606/en/
Contacts
Kathleen Nemeth
Vice President, Investor Relations
ir@omnicell.com
